NTHI NEONC TECHNOLOGIES HOLDINGS INC.

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance’s Trader Talk with Kenny Polcari in a podcast episode titled “AI and Biotech Take on Brain Cancer.”

As Trader Talk describes it: “When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (Nasdaq: NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc’s focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC’s medical school, and how global clinical trials are expanding the company’s reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It’s a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage.”

You can tune in to the episode on , , , or wherever you listen to your podcasts.

ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.



NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100 and NEO212 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

For more about NeOnc and its pioneering technology, visit .

Important Cautions Regarding Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.

Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.

The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.

We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.

“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Company Contact:

i

Investor Contact:

James Carbonara

Hayden IR

(646)-755-7412



EN
04/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEONC TECHNOLOGIES HOLDINGS INC.

 PRESS RELEASE

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI...

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance’s Trader Talk with Kenny Polcari in a podcast episode titled “AI and Biotech Take on Brain Cancer.” As Trader Talk describes it: “When a biotech startup lands in a major index just months after its IPO, investors take ...

 PRESS RELEASE

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Q...

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signing of a definitive, binding Letter of Intent (LOI) to acquire all outstanding equity interests in a to-be-formed Delaware entity jointly owned by Dr. Ishwar K. Puri and Beth R. Levinson. The IP port...

 PRESS RELEASE

NeOnc Technologies Signs Definitive Agreement for $50 Million Strategi...

NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment CALABASAS, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has it has signed a definitive agreement for a $50 million strategic partnership with Quazar Investment. The definitive agreement follows NeOnc’s Board unanimously approving the company’s participation in the contemplated $50 mi...

 PRESS RELEASE

NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Co...

NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference CALABASAS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced that management will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025. Investors interested in scheduling a 1x1 meeting with management are invited to contact their BTIG representative directly or reach out to ABOUT NEONC TECHNOLOGI...

 PRESS RELEASE

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc. CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- In a press release issued earlier today by NeOnc Technologies Holdings, Inc. under the headline, "NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET," please note "today" in the headline and first paragraph should be "July 24, 2025." The corrected release follows:  NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch